DK2290108T3 - Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira, samt kimære dengue-vira - Google Patents

Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira, samt kimære dengue-vira

Info

Publication number
DK2290108T3
DK2290108T3 DK10181776.5T DK10181776T DK2290108T3 DK 2290108 T3 DK2290108 T3 DK 2290108T3 DK 10181776 T DK10181776 T DK 10181776T DK 2290108 T3 DK2290108 T3 DK 2290108T3
Authority
DK
Denmark
Prior art keywords
dengue viruses
development
well
attenuating
chimeric
Prior art date
Application number
DK10181776.5T
Other languages
English (en)
Inventor
Ching-Juh Lai
Stephen S Whitehead
Brian R Murphy
Kathryn A Hanley
Joseph E Blaney Jr
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of DK2290108T3 publication Critical patent/DK2290108T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24163—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
DK10181776.5T 2001-05-22 2002-05-22 Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira, samt kimære dengue-vira DK2290108T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29304901P 2001-05-22 2001-05-22
EP02739358A EP1402075B1 (en) 2001-05-22 2002-05-22 Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses

Publications (1)

Publication Number Publication Date
DK2290108T3 true DK2290108T3 (da) 2014-10-20

Family

ID=23127420

Family Applications (4)

Application Number Title Priority Date Filing Date
DK02739358.6T DK1402075T3 (da) 2001-05-22 2002-05-22 Udvikling af egnede mutationer til svækkelse af dengue-vira samt kimære dengue-vira
DK10181786.4T DK2290109T3 (da) 2001-05-22 2002-05-22 Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira samt kimære dengue-vira
DK10181776.5T DK2290108T3 (da) 2001-05-22 2002-05-22 Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira, samt kimære dengue-vira
DK10181804.5T DK2292802T3 (da) 2001-05-22 2002-05-22 Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira og kimære dengue-vira

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK02739358.6T DK1402075T3 (da) 2001-05-22 2002-05-22 Udvikling af egnede mutationer til svækkelse af dengue-vira samt kimære dengue-vira
DK10181786.4T DK2290109T3 (da) 2001-05-22 2002-05-22 Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira samt kimære dengue-vira

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10181804.5T DK2292802T3 (da) 2001-05-22 2002-05-22 Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira og kimære dengue-vira

Country Status (8)

Country Link
US (10) US7226602B2 (da)
EP (5) EP1402075B1 (da)
AU (2) AU2002312011B2 (da)
BR (2) BRPI0209943B8 (da)
CA (5) CA2755964C (da)
DK (4) DK1402075T3 (da)
ES (4) ES2399420T3 (da)
WO (1) WO2002095075A1 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2355719T3 (es) 2002-05-03 2011-03-30 The United States Government As Represented By The Department Of Health And Human Services Vacuna contra el dengue que contiene una deleción común de 30 nucleótidos en la utr en 3' del dengue tipos 1 y 2.
US7851194B2 (en) * 2004-06-14 2010-12-14 The United States Of America As Represented By The Department Of Health And Human Services West Nile viruses with mutations in the 3′ terminal stem and loop secondary structure for use as live virus vaccines
US8124398B2 (en) 2005-04-24 2012-02-28 Sanofi Pasteur Biologics Co. Recombinant flavivirus vaccines
WO2006134433A1 (en) 2005-06-17 2006-12-21 Sanofi Pasteur Dengue serotype 1 attenuated strain
DE602006015807D1 (de) * 2005-06-17 2010-09-09 Ct S For Disease Control & Pre Abgeschwächter dengue-serotyp-2-stamm
CU23578A1 (es) * 2005-09-16 2010-09-30 Ct Ingenieria Genetica Biotech Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
US20100316670A1 (en) * 2007-06-14 2010-12-16 Blaney Joseph E Chimeric sle/dengue type 4 antigenic viruses
CN105944095B (zh) 2008-03-05 2021-04-02 赛诺菲巴斯德有限公司 一种使含佐剂的疫苗组合物稳定的方法
WO2009152147A2 (en) * 2008-06-09 2009-12-17 La Jolla Institute For Allergy And Immunology Compositions and methods for dengue virus (dv) treatment and vaccination
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
NZ700477A (en) 2009-02-17 2016-04-29 Glaxosmithkline Biolog Sa Inactivated dengue virus vaccine with aluminium-free adjuvant
EP2430444B1 (en) * 2009-05-12 2014-01-08 Janssen R&D Ireland Method for identifying inhibitors against dengue virus
CN102449172A (zh) 2009-06-01 2012-05-09 伊维拉根公司 施用针对登革病毒的疫苗的组合物和方法
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
EP2442711B1 (en) * 2009-06-17 2024-02-21 Human Chimp Pty Ltd Determining haemodynamic performance
AU2010286368B2 (en) 2009-08-31 2015-09-03 Gen-Probe Incorporated Dengue virus assay
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
US10308689B2 (en) 2010-06-24 2019-06-04 La Jolla Institute For Allergy And Immunology Dengue virus (DV) polypeptide sequences, T cell epitopes and methods and uses thereof
US8895028B2 (en) 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
KR20150036592A (ko) 2012-07-24 2015-04-07 사노피 파스퇴르 백신 조성물
EP3010536A4 (en) 2013-06-21 2016-11-30 Merck Sharp & Dohme DENGUE VIRUS VACCINE COMPOSITIONS AND METHODS FOR USE THEREOF
JP6764348B2 (ja) 2014-02-11 2020-09-30 ビステラ， インコーポレイテッド デングウイルスに対する抗体分子およびその使用
BR112017004452B1 (pt) 2014-09-05 2023-12-12 The Research Foundation For The State University Of New York Vírus atenuado, arbovírus atenuado, seus usos, composição de vacina, método de produção de um genoma de vírus atenuado, método de produção de um arbovírus atenuado e genoma de arbovírus atenuado
AU2015369875A1 (en) 2014-12-22 2017-06-15 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
JP6893174B2 (ja) * 2015-01-16 2021-06-23 タケダ ワクチン，インコーポレイテッド 粒子に含まれる逆転写酵素活性の検出
US10105434B2 (en) 2015-08-03 2018-10-23 The United States Of America As Represented By The Secretary Of The Navy Immune enhancing recombinant dengue protein
EP3355916A4 (en) 2015-09-30 2018-08-29 Panacea Biotec Limited Stable live attenuated recombinant dengue vaccine
BE1024160B9 (fr) 2015-12-22 2017-12-06 Glaxosmithkline Biologicals Sa Formulation immunogène
BR112018068342A2 (pt) * 2016-03-11 2019-01-15 Univ Johns Hopkins vacina de vírus zika vivo atenuado
EP3433274A1 (en) 2016-03-25 2019-01-30 Visterra, Inc. Formulation of antibody molecules to dengue virus
CN109196095A (zh) * 2016-04-14 2019-01-11 新加坡国立大学 产生活减毒疫苗的快速方法
WO2018129160A1 (en) 2017-01-06 2018-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Live attenuated flavivirus vaccines and methods of using and making same
JP7313345B2 (ja) 2017-10-05 2023-07-24 サノフィ・パスツール デング熱に対するブースターワクチン接種のための組成物
IL316312A (en) 2017-12-07 2024-12-01 Merck Sharp ַ& Dohme Llc Dengue virus vaccine compound formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5494671A (en) * 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
GB9513371D0 (en) 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US6074865A (en) * 1995-07-20 2000-06-13 The United States Of America As Represented By The Secretary Of The Army Recombinant dengue virus DNA fragment
US6455509B1 (en) * 1996-06-04 2002-09-24 The United States Of America As Represented By The Secretary Of The Navy Dengue nucleic acid vaccines that induce neutralizing antibodies
US6537557B1 (en) * 1999-03-26 2003-03-25 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-4 virus vaccine
AU779280B2 (en) * 1999-03-26 2005-01-13 Walter Reed Army Institute Of Research Multivalent dengue virus vaccine

Also Published As

Publication number Publication date
BRPI0209943B8 (pt) 2021-05-25
BR122019026154B1 (pt) 2020-11-24
CA3114957C (en) 2022-02-08
EP1402075A4 (en) 2005-05-11
CA2966716C (en) 2019-11-26
CA3060687A1 (en) 2002-11-28
EP2290109A2 (en) 2011-03-02
US8632782B2 (en) 2014-01-21
EP2292802A3 (en) 2011-03-23
EP2290108A3 (en) 2011-03-09
US10500264B2 (en) 2019-12-10
AU2008203275A1 (en) 2008-08-14
DK2292802T3 (da) 2015-03-09
US7560118B2 (en) 2009-07-14
EP2940154A1 (en) 2015-11-04
US20150064214A1 (en) 2015-03-05
BR0209943A (pt) 2004-03-30
CA3114957A1 (en) 2002-11-28
US7226602B2 (en) 2007-06-05
AU2008203275B2 (en) 2011-11-10
ES2512715T3 (es) 2014-10-24
ES2533085T3 (es) 2015-04-07
US8039003B2 (en) 2011-10-18
CA3060687C (en) 2021-05-04
US20070092534A1 (en) 2007-04-26
EP1402075A1 (en) 2004-03-31
US20180008693A1 (en) 2018-01-11
US11318196B2 (en) 2022-05-03
US20090263424A1 (en) 2009-10-22
US20200085939A1 (en) 2020-03-19
WO2002095075A1 (en) 2002-11-28
US9707287B2 (en) 2017-07-18
CA2755964C (en) 2017-06-27
CA2966716A1 (en) 2002-11-28
AU2002312011B2 (en) 2008-04-24
ES2523168T3 (es) 2014-11-21
EP1402075B1 (en) 2012-11-14
USRE45016E1 (en) 2014-07-15
CA2755964A1 (en) 2002-11-28
US20120114694A1 (en) 2012-05-10
EP2290108A2 (en) 2011-03-02
USRE45123E1 (en) 2014-09-09
EP2290109B1 (en) 2014-08-13
EP2290108B1 (en) 2014-07-23
EP2290109A3 (en) 2011-03-16
CA2448329C (en) 2011-10-25
EP2292802B1 (en) 2015-01-14
EP2940154B1 (en) 2019-05-22
CA2448329A1 (en) 2002-11-28
US20050010043A1 (en) 2005-01-13
BRPI0209943B1 (pt) 2020-10-13
ES2399420T3 (es) 2013-04-01
DK1402075T3 (da) 2013-02-11
EP2292802A2 (en) 2011-03-09
BR122019026154B8 (pt) 2021-07-27
DK2290109T3 (da) 2014-11-10
USRE45053E1 (en) 2014-07-29

Similar Documents

Publication Publication Date Title
DK2290109T3 (da) Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira samt kimære dengue-vira
DE60139127D1 (de) Von hepatitis c virus
DE60329367D1 (de) Verwendung bei der bekämpfung von hepatitis c virusinfektion
DK1620437T3 (da) 5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension
NO20023283D0 (no) Flammestopper
DK1501921T4 (da) Forbedrede virusrensningsmetoder
DK1448523T3 (da) Heterocycliske forbindelser samt metoder til anvendelse deraf
IS8476A (is) Lifrarbólgu C-veirutálmar
IS8475A (is) Lifrarbólgu C-veirutálmar
DE50109189D1 (de) Schaufelanordnung mit Dämpfungselementen
DK1309545T3 (da) Fremgangsmåde til fremstilling af alkylarylsulfonater
IS7520A (is) Pyrimidínonefnasambönd, samsetningar og aðferðir
DK1373256T3 (da) CCR5-antagonister, der er nyttige til behandling af AIDS
FR15C0005I2 (fr) Composes derives de benzothiazole, compositions et utilisations
NO20035121D0 (no) Ny anvendelse
NO20030239D0 (no) Modifisert virus
DE50206722D1 (de) Zusammensetzungen, enthaltend quaternäre Ammoniumverbindungen
EP1692279A4 (en) VIRUS PREPARATIONS CONTAINING A CONSERVATIVE
DE60202489D1 (de) Lysin enthaltende kautablette
DK1605759T3 (da) Herbicid blanding, der omfatter ufarliggörelsesmiddel
DE602004010285D1 (de) Statisches latch
DE60201463D1 (de) Indanon-Derivate als Duftstoffe
DE60336338D1 (de) Sulfonylaminopyrazole als pestizide
DE50209313D1 (de) Selektive arylguanidinpeptide als urokinaseinhibitoren
DE50211466D1 (de) Substituierte 4-aminocyclohexanolderivate